Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells

T. Matsui, Shoichi Yamagishi, K. Nakamura, Hiroyoshi Inoue, M. Takeuchi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The interaction between advanced glycation end-products (AGEs) and their receptors mediates the progressive alteration in renal architecture and loss of renal function in diabetic nephropathy. This study investigated whether nifedipine, a widely used anti-hypertensive drug, suppresses expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to inflammatory sites, in AGE-exposed human cultured mesangial cells. Cells were treated with 100 μg/ml AGE-bovine serum albumin (BSA) or non-glycated BSA in the presence or absence of 1 μM nifedipine or 50 nM diphenylene iodonium, an inhibitor of reduced nicotinamide-adenine dinucleotide phosphate oxidase, for 4 or 24 h. Expression of MCP-1 mRNA was measured using a semi-quantitative reverse transcription-polymerase chain reaction; MCP-1 protein production was measured using an enzyme-linked immunosorbent assay. AGEs significantly increased both MCP-1 mRNA expression and protein production in mesangial cells; this increase was blocked by both nifedipine and diphenylene iodonium. These results suggest that nifedipine could play a protective role against early diabetic nephropathy by suppressing MCP-1 overexpression via blockade of AGE signalling in mesangial cells.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalJournal of International Medical Research
Volume35
Issue number1
Publication statusPublished - 2007 Jan
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Mesangial Cells
Chemokine CCL2
Calcium Channel Blockers
Nifedipine
Cultured Cells
Diabetic Nephropathies
Kidney
Immunosorbents
Messenger RNA
Polymerase chain reaction
Transcription
Bovine Serum Albumin
NADP
Chemokines
Antihypertensive Agents
Reverse Transcription
Monocytes
Assays
Oxidoreductases

Keywords

  • Advanced glycation end-product (AGEs)
  • Diabetic nephropathy
  • Monocyte chemoatiractant protein-1 (MCP-1)
  • Nifedipine
  • Oxidative stress

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. / Matsui, T.; Yamagishi, Shoichi; Nakamura, K.; Inoue, Hiroyoshi; Takeuchi, M.

In: Journal of International Medical Research, Vol. 35, No. 1, 01.2007, p. 107-112.

Research output: Contribution to journalArticle

@article{dc2519f82cb546ccadecbbc23b0a03a7,
title = "Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells",
abstract = "The interaction between advanced glycation end-products (AGEs) and their receptors mediates the progressive alteration in renal architecture and loss of renal function in diabetic nephropathy. This study investigated whether nifedipine, a widely used anti-hypertensive drug, suppresses expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to inflammatory sites, in AGE-exposed human cultured mesangial cells. Cells were treated with 100 μg/ml AGE-bovine serum albumin (BSA) or non-glycated BSA in the presence or absence of 1 μM nifedipine or 50 nM diphenylene iodonium, an inhibitor of reduced nicotinamide-adenine dinucleotide phosphate oxidase, for 4 or 24 h. Expression of MCP-1 mRNA was measured using a semi-quantitative reverse transcription-polymerase chain reaction; MCP-1 protein production was measured using an enzyme-linked immunosorbent assay. AGEs significantly increased both MCP-1 mRNA expression and protein production in mesangial cells; this increase was blocked by both nifedipine and diphenylene iodonium. These results suggest that nifedipine could play a protective role against early diabetic nephropathy by suppressing MCP-1 overexpression via blockade of AGE signalling in mesangial cells.",
keywords = "Advanced glycation end-product (AGEs), Diabetic nephropathy, Monocyte chemoatiractant protein-1 (MCP-1), Nifedipine, Oxidative stress",
author = "T. Matsui and Shoichi Yamagishi and K. Nakamura and Hiroyoshi Inoue and M. Takeuchi",
year = "2007",
month = "1",
language = "English",
volume = "35",
pages = "107--112",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "1",

}

TY - JOUR

T1 - Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells

AU - Matsui, T.

AU - Yamagishi, Shoichi

AU - Nakamura, K.

AU - Inoue, Hiroyoshi

AU - Takeuchi, M.

PY - 2007/1

Y1 - 2007/1

N2 - The interaction between advanced glycation end-products (AGEs) and their receptors mediates the progressive alteration in renal architecture and loss of renal function in diabetic nephropathy. This study investigated whether nifedipine, a widely used anti-hypertensive drug, suppresses expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to inflammatory sites, in AGE-exposed human cultured mesangial cells. Cells were treated with 100 μg/ml AGE-bovine serum albumin (BSA) or non-glycated BSA in the presence or absence of 1 μM nifedipine or 50 nM diphenylene iodonium, an inhibitor of reduced nicotinamide-adenine dinucleotide phosphate oxidase, for 4 or 24 h. Expression of MCP-1 mRNA was measured using a semi-quantitative reverse transcription-polymerase chain reaction; MCP-1 protein production was measured using an enzyme-linked immunosorbent assay. AGEs significantly increased both MCP-1 mRNA expression and protein production in mesangial cells; this increase was blocked by both nifedipine and diphenylene iodonium. These results suggest that nifedipine could play a protective role against early diabetic nephropathy by suppressing MCP-1 overexpression via blockade of AGE signalling in mesangial cells.

AB - The interaction between advanced glycation end-products (AGEs) and their receptors mediates the progressive alteration in renal architecture and loss of renal function in diabetic nephropathy. This study investigated whether nifedipine, a widely used anti-hypertensive drug, suppresses expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to inflammatory sites, in AGE-exposed human cultured mesangial cells. Cells were treated with 100 μg/ml AGE-bovine serum albumin (BSA) or non-glycated BSA in the presence or absence of 1 μM nifedipine or 50 nM diphenylene iodonium, an inhibitor of reduced nicotinamide-adenine dinucleotide phosphate oxidase, for 4 or 24 h. Expression of MCP-1 mRNA was measured using a semi-quantitative reverse transcription-polymerase chain reaction; MCP-1 protein production was measured using an enzyme-linked immunosorbent assay. AGEs significantly increased both MCP-1 mRNA expression and protein production in mesangial cells; this increase was blocked by both nifedipine and diphenylene iodonium. These results suggest that nifedipine could play a protective role against early diabetic nephropathy by suppressing MCP-1 overexpression via blockade of AGE signalling in mesangial cells.

KW - Advanced glycation end-product (AGEs)

KW - Diabetic nephropathy

KW - Monocyte chemoatiractant protein-1 (MCP-1)

KW - Nifedipine

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=33947580463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947580463&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 107

EP - 112

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 1

ER -